Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
17 citations
,
September 2013 in “The International Journal of Neuropsychopharmacology”
August 2021 in “Case Reports” A woman thought to have rosacea was actually suffering from Frontal Fibrosing Alopecia, a hair loss condition. Despite treatment, her condition didn't change, showing the importance of accurate early diagnosis.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
14 citations
,
January 2014 in “Indian Journal of Dermatology Venereology and Leprology” Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.
September 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Isotretinoin at low doses effectively treats facial papules in frontal fibrosing alopecia.
April 2023 in “Revista colombiana de reumatología” JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
June 2018 in “International Review of Intellectual Property and Competition Law”
July 2022 in “Research Square (Research Square)” Lower PPARγ levels and specific gene variations are linked to more severe Frontal Fibrosing Alopecia.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
6 citations
,
November 2020 in “Chinese Medical Journal” Combining minoxidil and fibroblast growth factor is more effective for treating male hair loss than using either alone.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
2 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The botanical treatment for hair loss shows promise, especially for children.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.
A new treatment using conjugated linoleic acid nanovesicles can rejuvenate hair follicles and improve hair growth in androgenic alopecia.
2 citations
,
September 1989 in “PubMed” Canrenone effectively reduced hair growth and testosterone levels in women with excessive hairiness.
April 2018 in “Journal of Investigative Dermatology”
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
8 citations
,
December 2020 in “Skin appendage disorders” Low-dose oral minoxidil helped regrow eyebrows in women with Frontal Fibrosing Alopecia.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity”
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.